Statement Re CardioQ-ODM

RNS Number : 6192I

Deltex Medical Group PLC

21 November 2008

 

Deltex Medical Group plc

Australian doctors publish positive meta-analysis on CardioQ-ODM™

21 November 2008 - Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the UK's leading haemodynamic monitoring company and global leader in oesophageal Doppler monitoring ('ODM'), announces today the publication of a further meta-analysis on ODM.

Doctors from St Vincent's Hospital in Melbourne have published their meta-analysis of ODM in the current issue of the Journal of the American College of Surgery. Their conclusions were that 'using ODM to guide intraoperative IV fluid therapy will increase the administration of intraoperative IV colloid fluid and reduce length of hospital stay, time to resume full oral diet, and postoperative morbidity or complications'.

The Company has this week received from its Australian distributor, Focus Medical, orders for ten CardioQ-ODM monitors and a standing order for 40 probes a month to meet the growing demand for ODM in Australia.

Deltex Medical's Chief Executive, Andy Hill commented:

'This is the third highly positive meta-analysis of ODM to be published in 2008 alone: the momentum behind establishing ODM as a standard of care during surgery is gathering pace in countries like Australia where our market development is still at an early stage.'

For further information, please contact:-

Deltex Medical Group plc            01243 774 837

Nigel Keen, Chairman                      [e-mail]

Andy Hill, Chief Executive                [e-mail]

Ewan Phillips, Finance Director        [e-mail] 

Gavin Anderson & Company        0207 554 1400

Deborah Walter                             [e-mail]

Robert Speed                                [e-mail]

Nominated Adviser & Broker

Charles Stanley Securities            020 7149 6000

Philip Davies                                   [e-mail] 

Russell Cook                                  [e-mail] 

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,500 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 100 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

NRAFKKKBABDDADB